Fig 6. Embelin treatment downregulates mortalin expression and enhances the nuclear localization and transcriptional activation of p53.

(A) Mortalin and p53 expression levels in control and embelin-treated breast cancer (MCF7) cells, as detected by Western blotting. Actin was used as an internal control. Quantitation of protein expression levels from three independent experiments performed using ImageJ software is shown in the lower panel. (B) Immunostaining of mortalin and p53 in control and embelin (10 μM)-treated (MCF7) cells showing reduction in mortalin level and increased in nuclear localization of p53 in response to embelin treatment. Intensity measurement of immunostaining was done by ImageJ software. (C) Relative p53 activity in control and embelin-treated cells was determined by p53-dependent luciferase reporter assay. Statistical significance was calculated using QuickCals t-test calculator (*P<0.05, **P<0.01, ***P<0.001).